SnowWorld N.V.

Regulatory Filings • Dec 9, 2010

P R E S S R E L E A S E

Lelystad, the Netherlands, 8 December 2010

Update on strategic review of Fornix

Since the divestment by Fornix BioSciences N.V. (Fornix) of its Allergy Division as approved on the extra-ordinary general meeting of shareholders held on 29 June 2010, Fornix has been exploring various strategic options for the future direction of the company in the interest of all its stakeholders.

Fornix has explored and researched the possibility of the expansion of its Medical Aids division as previously communicated and has concluded that this option is not preferable in a public company environment. Fornix has therefore initiated a process to divest its Medical Aids division (Laprolan) as well as its German division (Artu Biologicals).

In parallel the boards are researching the strategic option of a reverse merger or takeover of Fornix, with a preference to seeking a candidate in the healthcare sector. The boards consider this as the preferred option for all of Fornix's stakeholders based on Fornix's sound legacy as a public entity and its favourable cash position. A thorough analysis of this option has taken longer than initially anticipated, whilst progress has been made.

In the event this option is not realizable in an acceptable timeframe the logical consequences of this review will lead to a liquidation and possible de-listing of Fornix from the Euronext Amsterdam exchange. In addition to working on these options, the boards are also working on reducing the overhead costs of Fornix significantly whilst not compromising governance and continuity.

E N D O F P R E S S R E L E A S E

For additional information, please contact: Fornix BioSciences N.V. C.L. Bergman CEO Tel. +31 (0) 320) 26 79 33

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) engaged in the distribution of medical aids and medical and nursing consumables. The company, which operates sites in Lelystad, Beuningen and Hamburg, currently employs approximately 40 people. Fornix BioSciences N.V. operates mainly in the Netherlands and Germany. Its activities are conducted by two divisions that are both engaged primarily in the sale and distribution of medical aids.

The Medical Aids Division consists of Laprolan, which is located in Beuningen, and specialises in the sale, marketing and distribution in the Netherlands of a wide range of medical aids and medical and nursing consumables.

Artu Biologicals Deutschland is engaged in the marketing, sale and distribution of a growing range of medical aids and a range (to be phased out) of immunotherapeutic allergen products in Germany.